mvg introduction
play

MVG introduction Types of variation application Some differences - PowerPoint PPT Presentation

Jan 21, 2023 •35 likes •195 views

MVG introduction Types of variation application Some differences between AVG & MVG Scope Timeline Additional notes Fee Changes leading to new product registration References Implementation 1 Types of

  1. MVG introduction  Types of variation application  Some differences between AVG & MVG  Scope  Timeline  Additional notes  Fee  Changes leading to new product registration  References  Implementation 1

  2. Types of Variation application  17 Major Variation (MaV) - Prior approval (tell and do) - Significantly and/or directly affects safety, efficacy, quality - Does not fall into MiV or new registration  36 Minor Variation Prior Approval (MiV-PA) - Prior approval (tell and do) - minimal / no significant impact on safety, efficacy, quality  11 Minor Variation Notification (MiV-N) - Notification (do and tell) - Administrative changes with no impact on safety, efficacy, quality 2

  3. Some differences between AVG & MVG  No change in the categorization of variation but minor adjustment to conditions and supporting documents.  Currently NPCB does not allow multiple site for the same manufacturing step of finished product (MaV-5, MaV- 6, MiV-PA4, MiV-PA30, MiV-N8)  Added: MaV-4: Major change of manufacturing process for DS a) (where CEP is not available) MiV-PA3: Change of PIL b) MiV-N2: Change of importer and store address c) 3

  4. Scope of current MVG  Pharmaceutical products for human use (NCEs, prescription, non prescription X-full products) 4

  5. Timeline – Minor Variation Notification (MiV-N) Variation type MiV- N (do and tell) Procedure If the notification fulfils the requirements (conditions and supporting documents) as per described under MiV-N, product registration holder must notify NPCB. NPCB shall acknowledge receipt of a notification. Timeline for Within 20 working days following receipt of a NPCB to notification. acknowledge notification  A MiV-N application may be rejected with the consequence that the PRH must cease to apply the already implemented variation.  PRH must ensure validity of the manufacturer’s license prior to implementation of MiV-N. 5

  6. Timeline – Minor Variation Prior Approval (MiV-PA) & Major Variation (MaV) Variation type MiV-PA MaV Approval or • Approval or first correspondence • Approval or first correspondence correspondence shall be issued to product shall be issued to product registration holder within 45 registration holder within 60 working days, provided all working days, provided all conditions conditions and supporting and supporting documents are documents are fulfilled. fulfilled. • Subsequent correspondences which • Subsequent correspondences which fulfill the requirements will be fulfill the requirements will be granted approval within 20 working granted approval within 30 working days. days. • After third correspondence, • After third correspondence, application may be rejected if still application may be rejected if still does not fulfill requirements. does not fulfill requirements. Timeline for Within 20 working days failing which Within 30 working days failing which product application will be rejected. Auto- application will be rejected. Auto- registration reminder will be sent 10 working days reminder will be sent 15 working days holder to reply before the deadline. before the deadline. 6

  7. Timeline – Minor Variation Prior Approval (MiV-PA) & Major Variation (MaV) Product Registration Holder NPCB MiV-PA 0 0 MaV 45 / 60 working days to issue approval or first correspondence 20 / 30 working days for first correspondence 20 / 30 working days to issue approval or second correspondence 20 / 30 working days for second correspondence 20 / 30 working days to issue approval or third correspondence 20 / 30 working days for third correspondence 20 / 30 working days to know the 20 / 30 working days to issue approval or final status rejection 7

  8. Timeline – Implementation of variation (MiV-PA & MaV)  Within 6 months after the PRH has been informed of the approved variations. 8

  9. Additional Notes  Re-categorization: May have to withdraw & resubmit  Revised PI & labeling subject to current requirement: DRGD a) Circulars b) What is registered in the system (includes c) administrative data of Part I)  NPCB’s right: Re-categorize a) Ask for additional information b) Reject application if incomplete c) 9

  10. Proposed variation fee per variation type per product Type of Application Full evaluation Abridge evaluation (A, X) (N, T) MiV-N No fee No fee MiV-PA RM150 RM50 MaV RM300 RM100 Additional indication RM1000 Not applicable 10

  11. Fee for change of manufacturing site per product Type of Application Pharmaceutical Traditional (A, X, N) (T) I RM500 RM100 II, III, IV, V RM1000 RM500 11

  12. Changes leading to new product registration  Changes to the Active Pharmaceutical Ingredient (API). Change of the API to a different API including change in the salt or • isomer form of the API. Inclusion of an additional API to a multicomponent product. • Removal of one API from a multicomponent product. • Change in the strength of one or more APIs. • Increase in overage. •  Changes to the pharmaceutical form/dosage form.  Changes in the route of administration (exception for parenteral route).  Changes in the manufacturing site of drug product. • Addition of a new manufacturing site to the currently approved site for the same manufacturing process. • Change from a currently approved contract manufacturer or own plant to another contract manufacturer not under crisis situation. 12

  13. Others  Lead compendium refers to British Pharmacopeia (BP), European Pharmacopeia (EP), Japan Pharmacopoeia (JP) and United States Pharmacopeia (USP).  This list of variations is not exhaustive and will be amended from time to time as and when the need arises. Any variations not yet listed in this guideline should be justified and decided by NPCB.  Appropriate reference can be made to:  ASEAN Variation Guideline for Pharmaceutical Products 2012  EMA Classification Guidance On Minor Variations of Type IA, Minor Variations of Type IB And Major Variations of Type II.  SUPAC-IR: Immediate-Release Solid Oral Dosage Forms: Scale-Up And Post- Approval Changes: Chemistry, Manufacturing And Controls, In Vitro Dissolution Testing, And In Vivo Bioequivalence Documentation.  SUPAC-MR: Modified Release Solid, Oral Dosage Forms, Scale-Up and Post approval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation.  WHO Guidance On Variations To A Prequalified Product Dossier. 13

  14. MVG implementation in Malaysia  1 July 2013 – Minor Variation Notification (MiV- N) including MiV-N timeline  1 January 2014 – a) Conditions & documentations for MaV & MiV- PA b) grace period for implementation by PRH after approval of variation  Payment for variation, timeline for MaV & MiV-PA – with Quest 3+  Type I COS & additional indication payment via manual route after approval of proposed fee by Bahagian Kewangan 14

  15. Moving on from here  Submission mode: a) Products registered in Quest 2: online b) Products registered in Quest 3: manual - In your cover letter, pls leave your contact details eg. e-mail, phone no.) - Table of comparison of the current and propose data  Types of variation for the interim period: a) Starting 1 July 2013 : MiV-N replaces Type I variation. PRH required to fill up MiV-N form. b) Variations that are not listed under MiV-N becomes a Type II variation. c) Starting 1 January 2014 : Conditions & documentations according to MVG. The processing timeline for MaV and MiV-PA is the same for the interim period. 15

  16. 16

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend

INTRODUCTION INTRODUCTION INTRODUCTION INTRODUCTION INTRODUCTION INTRODUCTION INTRODUCTION

INTRODUCTION INTRODUCTION INTRODUCTION INTRODUCTION INTRODUCTION INTRODUCTION INTRODUCTION

TRAINING COURSE ON SOCIAL PROTECTION & FORMALIZATION TRINIDAD AND TOBAGO MARCH 15, 2017 INTRODUCTION INTRODUCTION INTRODUCTION INTRODUCTION INTRODUCTION INTRODUCTION INTRODUCTION INTRODUCTION Design of the NIS Assistance from the

547 views • 23 slides
INTRODUCTION Introduction 2/42 INTRODUCTION Alternations I am giving bread to the

INTRODUCTION Introduction 2/42 INTRODUCTION Alternations I am giving bread to the

Patterns of variation in the expression of case and agreement Andrs Brny Leiden University Centre for Linguistics 9 November 2019, BaSIS Workshop a.barany@hum.leidenuniv.nl INTRODUCTION Introduction 2/42 INTRODUCTION

1.37k views • 42 slides
Introduction Introduction Introduction Introduction Outline Motivation Failures

Introduction Introduction Introduction Introduction Outline Motivation Failures

Introduction Introduction Introduction Introduction Outline Motivation Failures Definition and concepts Process and product properties Principles SE Approaches Motivation Software and the economy The economies of

1.03k views • 49 slides
Introduction Introduction Introduction Nationwide Cause for Concern 1

Introduction Introduction Introduction Nationwide Cause for Concern 1

Introduction Introduction Introduction Nationwide Cause for Concern 1 https://www.cdc.gov/std/stats17/infographic.htm Introduction Epidemiology in Western Colorado CPHE Surveillance Data Report, May 2018 Chlamydia Epidemiology in Western

977 views • 39 slides
DAQ introduction Purpose of this talk : (1) Introduction for those who have not been in every

DAQ introduction Purpose of this talk : (1) Introduction for those who have not been in every

DAQ introduction Purpose of this talk : (1) Introduction for those who have not been in every meeting (2) Some ideas of diagrams for section 7.1 (Introduction) of TP. Giles Barr 25 Jan 2018, Pembroke College On DUNE, the reality is there is a

474 views • 10 slides
INTRODUCTION cf. Schneider, Chapter 1 INTRODUCTION THEY ARE OUT TO GET YOU INTRODUCTION WHAT

INTRODUCTION cf. Schneider, Chapter 1 INTRODUCTION THEY ARE OUT TO GET YOU INTRODUCTION WHAT

ADVANCED COMPUTER SECURITY INTRODUCTION cf. Schneider, Chapter 1 INTRODUCTION THEY ARE OUT TO GET YOU INTRODUCTION WHAT IS SECURITY? A systems security policies describe What the system is supposed to do Store and provide access

479 views • 16 slides
Overview Introduction to SMIL Introduction to W3C and XML Introduction to SMIL

Overview Introduction to SMIL Introduction to W3C and XML Introduction to SMIL

Overview Introduction to SMIL Introduction to W3C and XML Introduction to SMIL Writing a SMIL file Adding Media Objects Martin Halvey Clipping media files January 2008 Timing and Synchronising Layout World Wide

387 views • 14 slides
14 Introduction Introduction Bad guys can put malware into Example: hosts

14 Introduction Introduction Bad guys can put malware into Example: hosts

Introduction Introduction source Encapsulation ISO/OSI reference model message M application segment H t H t M transport network datagram H n H n H t M presentation: allow applications to frame link H l H n H t M interpret

583 views • 4 slides
Previous Lecture Introduction to SMIL 2 Introduction to W3C and XML Introduction to SMIL

Previous Lecture Introduction to SMIL 2 Introduction to W3C and XML Introduction to SMIL

Previous Lecture Introduction to SMIL 2 Introduction to W3C and XML Introduction to SMIL Writing a SMIL file Adding Media Objects Martin Halvey Clipping media files January 2008 Timing and Synchronising Layout

322 views • 8 slides
Lecture 1 Andreas Habegger Introduction Zynq Introduction Zynq Introduction Zynq PS vs. PL

Lecture 1 Andreas Habegger Introduction Zynq Introduction Zynq Introduction Zynq PS vs. PL

Introduction Zynq Lecture 1 Andreas Habegger Introduction Zynq Introduction Zynq Introduction Zynq PS vs. PL Processing System Processor Peripherals Data Buses AXI Bus Conclusion BTE5380 - Embedded Systems Octobre 2014 Andreas Habegger

1.81k views • 30 slides
2018.06 01 SMILE5 Introduction S E 5 02 Alpha Cloud M I L 03 Company Introduction 04

2018.06 01 SMILE5 Introduction S E 5 02 Alpha Cloud M I L 03 Company Introduction 04

2018.06 01 SMILE5 Introduction S E 5 02 Alpha Cloud M I L 03 Company Introduction 04 Project References S E 5 PART.1 SMILE5 Introduction M I L Introduction STORION-SMILE5 Residential Energy Storage System Inverter 5kW Output Input

1.06k views • 25 slides
Introduction to CICS Course introduction Course introduction What is CICS? What is an

Introduction to CICS Course introduction Course introduction What is CICS? What is an

Introduction to CICS Course introduction Course introduction What is CICS? What is an application server? Why use an application server? Course introduction Services provided by CICS How CICS applications are defined Scaling CICS to meet

1.84k views • 146 slides
Network Visualization Introduction Presented by Shahed Introduction Introduction Basic

Network Visualization Introduction Presented by Shahed Introduction Introduction Basic

Network Visualization Introduction Presented by Shahed Introduction Introduction Basic building blocks Node Links (relationship between nodes) Spatial information Network data

584 views • 9 slides
Introduction Introduction (1) Main argument of the paper: universities are not only

Introduction Introduction (1) Main argument of the paper: universities are not only

Le jugement des pairs comme outil de management des universits Peer-review as a management tool Christine Musselin (CSO, Sciences Po et CNRS) Avril 2013, Lirrsistible ascension du capitalisme acadmique Introduction Introduction (1)

590 views • 28 slides
Introduction Introduction to storage and to storage and filesystems filesystems Introduction

Introduction Introduction to storage and to storage and filesystems filesystems Introduction

Moreno Baricevic Gilberto Daz Axel Kohlmeyer Stefano Cozzini ULA ICTP CNR-IOM DEMOCRITOS Merida, VENEZUELA Trieste, ITALY Trieste, ITALY Introduction Introduction to storage and to storage and filesystems filesystems Introduction

1.19k views • 51 slides
JABLOTRON JA-100 introduction November 2011 Introduction Todays goals First introduction of

JABLOTRON JA-100 introduction November 2011 Introduction Todays goals First introduction of

JABLOTRON JA-100 introduction November 2011 Introduction Todays goals First introduction of the brand new JA-100 alarm system Visions Basic architecture System components Setting Help us with final validations You are the FIRST ones

1.69k views • 111 slides
Medical Marijuana: Is Green & Leafy Really Good for You? Mary E. Peterson, RN, ANP-BC, AOCNP

Medical Marijuana: Is Green & Leafy Really Good for You? Mary E. Peterson, RN, ANP-BC, AOCNP

2/14/2015 Medical Marijuana: Is Green & Leafy Really Good for You? Mary E. Peterson, RN, ANP-BC, AOCNP Marci Andrejko, RN, OCN Dr. Parag Bharadwaj, MD Dr. Maggie McCallen, PharmD Objectives Review the history of cannabis/medical

698 views • 11 slides
Value Chains 1 Presentation to CRIBE Lignin Workshop Toronto December 5, 2018 Anne Waddell

Value Chains 1 Presentation to CRIBE Lignin Workshop Toronto December 5, 2018 Anne Waddell

Requirements of Global Value Chains 1 Presentation to CRIBE Lignin Workshop Toronto December 5, 2018 Anne Waddell and A.J. (Sandy) Marshall Points to be Covered 2 1. Why large firms are looking at this business? Price and performance

434 views • 12 slides
PUBLIC HEALTH Stacy Kancijanic, MA DEFINITIONS Counterfeit medicine is one that infringes on

PUBLIC HEALTH Stacy Kancijanic, MA DEFINITIONS Counterfeit medicine is one that infringes on

QUALITY OF MEDICINES IN PUBLIC HEALTH Stacy Kancijanic, MA DEFINITIONS Counterfeit medicine is one that infringes on a registered trademark. Substandard drugs fail to meet the specifications outlined by an accepted pharmacopeia or the

173 views • 15 slides
Future of the UCSF Parnassus Heights Campus Advisory Committee Meeting #4 November 19, 2019

Future of the UCSF Parnassus Heights Campus Advisory Committee Meeting #4 November 19, 2019

Future of the UCSF Parnassus Heights Campus Advisory Committee Meeting #4 November 19, 2019 Dinner Meeting Agenda Welcome and Opening Remarks Advisory Committee Process 2 Advisory Committee for the Future of UCSF Parnassus Heights

838 views • 45 slides
The Aemes Biorefinery Advanced Renewable Fuels and Chemicals

The Aemes Biorefinery Advanced Renewable Fuels and Chemicals

The Aemes Biorefinery Advanced Renewable Fuels and Chemicals Produced by Conversion of Exisng Biofuels Facilies May 2014 Disclaimer Certain of the

851 views • 46 slides
ANSI Homeland Security Standards Panel Global Supply Chain Security Standards and Annual Plenary

ANSI Homeland Security Standards Panel Global Supply Chain Security Standards and Annual Plenary

ANSI Homeland Security Standards Panel Global Supply Chain Security Standards and Annual Plenary Meeting Mary G. Foster, PharmD USP Chair, Expert Committee, Packaging, Storage & Distribution Aphena Pharma Solutions, VP Quality &

578 views • 8 slides
Roger Schwartz rschwartz@nachc.org ACA established State Exchanges ACA established State

Roger Schwartz rschwartz@nachc.org ACA established State Exchanges ACA established State

Roger Schwartz rschwartz@nachc.org ACA established State Exchanges ACA established State Exchanges Functions Functions: Provide individuals and small business employees with access to enrollment in Qualified Health Plans

263 views • 15 slides
Introduction Diverse range of customers Professionally & Technically Rich legacy of 50

Introduction Diverse range of customers Professionally & Technically Rich legacy of 50

Introduction Diverse range of customers Professionally & Technically Rich legacy of 50 Sound Management more than 50 Years years Un-paralleled & Timely Services Pan - India & Global presence About Us Established in the

618 views • 26 slides

More recommend